The STEP‐HFpEF study investigating the glucagon‐like peptide‐1 (GLP‐1) receptor agonist semaglutide in patients with heart failure (HF) and preserved ejection fraction (HFpEF) and obesity (body mass index [BMI] ≥30 kg/m2) showed larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss upon treatment with 2.4 mg per week semaglutide than placebo.1 This evidence concerns the gene GLP1R and obesity disorder.